ArticleRheumatology advances in practice2026
Incidence and prevalence of Takayasu arteritis in England before and after the COVID-19 pandemic: results from RECORDER.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Takayasu arteritis (TAK) is a rare large vessel vasculitis associated with substantial morbidity and mortality. Evidence on its epidemiology, including the COVID-19 pandemic's impacts, is incomplete. We aimed to describe the incidence and prevalence of TAK in England using national routinely collected healthcare data. Methods: Using Hospital Episode Statistics for the whole of England (Admitted Patient Care and Outpatients), we identified all people with the International Classification of Diseases, 10th revision code for TAK. We validated our case ascertainment and diagnosis date refinement strategies in five National Health Service Trusts and using the unique Imperial College TAK cohort of 123 confirmed cases. We calculated the incidence of TAK in England from 2006 to 2023 (cohort design), particularly focusing on the COVID-19 pandemic, and point prevalence for 1 July 2022 (cross-sectional design). Results were reported by key demographic variables. Results: The incidence of TAK in England was 1.3 (95% CI 1.3, 1.4) per million per year and was stable except for a 30% decrease in 2020-2021 (COVID-19 pandemic). The prevalence of TAK in mid-2022 was 22.5 per million (95% CI 21.3, 23.8). The median age at diagnosis was 53 years. Incidence and prevalence were both higher in women and in Asian/Asian British and Other ethnic groups. There was variation between different geographic areas, but socio-economic status did not have a marked effect. Conclusion: Nearly 1300 people have TAK in England, with >70 new cases each year apart from during the COVID-19 pandemic. These estimates, based on a 10-fold larger cohort than previous European studies, will be essential in planning and commissioning pandemic-prepared specialist services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.